[Optimal regime of intravenous administration of lincomycin in osteomyelitis]. 1977

V G Koroleva, and V M Fishman, and A A Firsov

The pharmacokinetics of lincomycin in the blood of 8 patients with osteomyelitis was studied on the drug single and uninterrupted intravenous administration in therapeutic doses. It was found that when the antibiotic was administered continuously according to the routine scheme, its therapeutic blood levels were attained only 1.5 hours after the drug infusion. The optimal regimen of lincomycin uninterrupted infusion providing its constant rate in combination with the single intravenous administration was estimated with the help of the constants of the two-compartment model of lincomycin pharmacokinetics. According to the calculations the rate of the antibiotic administration necessary for providing therapeutic levels should be 2.2 mg/kg in complex with the loading dose equal to 5.4 mg/kg. Practical trials showed that intravenous administration of lincomycin with the above regimen remained within therapeutic range already 10 to 20 minutes after the beginning of the drug infusion. Therefore, from the pharmacokinetic point of view the recommended regimen for lincomycin infusion should be considered preferable to that used presently.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008034 Lincomycin An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. Lincolnensin,Lincomycin, (2S-cis)-Isomer,Epilincomycin,Lincocin,Lincomycin A,Lincomycin Hydrochloride,Lincomycin Monohydrochloride,Lincomycin Monohydrochloride, (2S-cis)-Isomer,Lincomycin Monohydrochloride, (L-threo)-Isomer,Lincomycin Monohydrochloride, Hemihydrate,Lincomycin, (L-threo)-Isomer,Hemihydrate Lincomycin Monohydrochloride
D008297 Male Males
D010019 Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA. Osteomyelitides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

V G Koroleva, and V M Fishman, and A A Firsov
September 1973, Minerva medica,
V G Koroleva, and V M Fishman, and A A Firsov
December 1968, Ugeskrift for laeger,
V G Koroleva, and V M Fishman, and A A Firsov
August 2014, Tropical animal health and production,
V G Koroleva, and V M Fishman, and A A Firsov
March 1967, The Practitioner,
V G Koroleva, and V M Fishman, and A A Firsov
September 1986, The Veterinary record,
V G Koroleva, and V M Fishman, and A A Firsov
February 1986, Journal of clinical pharmacology,
V G Koroleva, and V M Fishman, and A A Firsov
July 1969, Current therapeutic research, clinical and experimental,
V G Koroleva, and V M Fishman, and A A Firsov
March 2006, Anesthesia and analgesia,
V G Koroleva, and V M Fishman, and A A Firsov
October 2005, The Cochrane database of systematic reviews,
V G Koroleva, and V M Fishman, and A A Firsov
January 1971, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!